RxDoctor Payments Data

Daniel Chavez Andia, MD

Internal Medicine · Chesterfield, MONPI 1598325359

Payments from drug & device makers

$1,992in general payments, 2019–2025

Across 39 payments — averaging $51.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$754
  • Johnson & Johnson$383
  • Novo Nordisk$376
  • Sunovion Pharmaceuticals Inc.$122
  • AbbVie$114
  • Pfizer$106
  • plus $136 from 4 others

What the payments were for

  • Food & beverage$1,992100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,992 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$48,535
Medicare patients
109
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban72$81,919
FarxigaDapagliflozin Propanediol30$39,731
TrulicityDulaglutide31$38,991
JanuviaSitagliptin Phosphate32$37,858
RybelsusSemaglutide23$36,680
OzempicSemaglutide25$31,543
XareltoRivaroxaban15$19,929
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,573
EntrestoSacubitril/Valsartan14$16,375
MounjaroTirzepatide11$11,314
InvokanaCanagliflozin12$9,218
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$6,099
Combivent RespimatIpratropium/Albuterol Sulfate11$5,519
Novolog FlexpenInsulin Aspart16$4,423
Atorvastatin Calcium374$3,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$106$81,91972 claims
Novo NordiskRybelsus, Ozempic$376$68,22348 claims
Lilly USA, LLCTrulicity, Mounjaro$48$50,30542 claims
AstraZenecaFarxiga$754$39,73130 claims
Johnson & JohnsonXarelto, Invokana$383$29,14727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →